US › Healthcare

Elicio Therapeutics Inc. (ELTX)

US · Healthcare · Biotechnology

$1.51+7.86%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.2M

EPS

$-0.43

EPS estimate

$-0.53

EPS came in at -0.43 against a street estimate of -0.53 — a beat of 18.9%.

Key statistics

Market cap

$37.9M

Forward P/E

0.0

P/B

5.17

Book value

$0.09

EPS (TTM)

$-2.16

52-week high

$16.00

52-week low

$1.25

50-day MA

$1.97

200-day MA

$6.68

Beta

2.00

Analyst view

Analysts rate Elicio Therapeutics Inc. a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $13.67.

Shareholding

Insiders

26.17%

Institutions

20.53%

Largest institutional holders

Fund	Stake
Shah Capital Management	4.61%
Knoll Capital Management LP	4.47%
BlackRock Inc	2.83%
Vanguard Capital Management, LLC	2.11%
Geode Capital Management, LLC	1.15%
State Street Corp	0.66%
Northern Trust Corp	0.48%
Ikarian Capital, LLC	0.37%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Elicio Therapeutics Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.